Prof Hope Rugo speaks to ecancer at BGICC 2019 in Cairo about neoadjuvant hormone therapy as a way to treat luminal breast cancer.
She discusses some of the key outcomes from the session including some early biological markers of endocrine sensitivity, one being a fall in Ki-67, that tends to show more positive outcomes.
Prof Rugo hopes to see more widespread use of the PEPI score in order to look at endocrine sensitivity when choosing therapeutic options.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
